Goldrosen Michael I MD Madison, WI - 53705

Goldrosen Michael I MD is categorized under Internal Medicine Practitioners in Madison, WI and active since 2011.

Goldrosen Michael I MD was established in 2011, and today employs 1 to 4, earning $500.000 to $999.999 per year. This is a Internal Medicine Practitioners business, which does work in the B2C market, and is classified as a Internal Medicine Practitioners, under code number 6211110 by the NAICS.

If you are seeking more information, feel free to contact Michael Goldrosen at the company’s single location by writing to 4410 Regent St, Madison, Wisconsin WI 53705 or by phoning (608) 233-9746. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.

Business Name: Goldrosen Michael I MD
Contact Person: Michael Goldrosen
Address: 4410 Regent St, Madison, Wisconsin 53705
Phone Number: (608) 233-9746
Website Address: apmadison.com
Annual Revenue (USD): $500.000 to $999.999
Founded: 2011
Location Type: Single Location
Employee Number: 1 to 4
Business Type: B2C (Business to Consumer)
Business Category: Internal Medicine Practitioners
SIC Code: 8011
NAICS Code: 6211110
Share This Business:

Goldrosen Michael I MD was started in 2011 to provide professional Internal Medicine Practitioners under the SIC code 8011 and NAICS code 6211110. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $500.000 to $999.999 per annum.

Feel free to contact Michael Goldrosen for inquiries that concern Goldrosen Michael I MD by calling the company number (608) 233-9746, as your correspondence is most welcome. Additionally, the physical location of the single location of Goldrosen Michael I MD can be found at the coordinates 43.06838,-89.45219 as well as the street address 4410 Regent St in Madison, Wisconsin 53705.

For its online presence, you may visit Goldrosen Michael I MD’s website at apmadison.com and engage with its social media outlets through on Twitter and on Facebook.